About Zhejiang Hisun Pharmaceutical Company

The company was founded in 1956 and was listed on A-shares in 2000. In 2012, Haizheng Pfizer Pharmaceuticals Co., Ltd. was established as a joint venture with Pfizer in the field of branded generic drugs. Selected as the country's first batch of “Innovative Enterprises”, “National Intellectual Property Demonstration Enterprises”, and “National Industrial Brand Cultivation Demonstration Enterprises”, and included in the “National Top 100 Pharmaceutical Industry Enterprises”, “China's Top 100 Chemical and Pharmaceutical Industry Industrial Enterprises with Comprehensive Strength”, and “2017 Top 100 Pharmaceutical Internationalization Enterprises”. The company's API business mainly includes traditional self-produced API export business, API contract customization business for global pharmaceutical companies, and domestic sales business. The company's main products are: injectable piperacillin sodium and tazobactam sodium (tetracycline), minocycline hydrochloride capsules (Hemman), amlodipine atorvastatin calcium tablets (up to 1), sirolimus tablets (rapamine), rosofastatin calcium tablets (hisuyan), injectable methylprednisolone sodium succinate (methanolone), injectable adenosylmethionine (Ximexin), orlistat, etc. Corporate honors: It has won honors such as “National High-tech Enterprise” and “National May 1st Labor Award”, and has been selected for honorary titles such as the country's first batch of “Innovative Enterprises”, “National Intellectual Property Demonstration Enterprise”, and the Zhejiang Provincial Government Quality Award.